Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and
correlated with hospital infections, but they have been evolving as an increasing cause of …

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)–
producing pathogens is recognized globally as one of the most pressing concerns facing the …

Introduction: Extended spectrum β-lactamases (ESBL) and AmpC β-lactamases are
increasing causes of resistance in many Gram-negative pathogens of common infections …

Background Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a
frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used …

Therapy of infections caused by extended‐spectrum β‐lactamase (ESBL)‐producing
bacteria with an antimicrobial to which they are resistant results in treatment failure, higher …

Introduction: The spread of extended-spectrum β–lactamase (ESBL)-producing
Enterobacteriaceae has become a major public health threat worldwide. Area covered: A …

The ongoing pandemic of extended-spectrum β-lactamase-producing Enterobacteriaceae
(ESBL-E) is responsible for a global rise in carbapenem consumption that may hasten the …

The current β-lactamase classifications have reached a high level of complexity, making
them less accessible to clinicians, infection control professionals, hospital management and …

Objectives To study the comparative mortality associated with carbapenems and alternative
antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive …

Traditionally, physicians have not used cefepime (a fourth-generation cephalosporin with
greater stability against β-lactamases) or β-lactam/β-lactamase inhibitors (BLBLIs) for …